Simcere Receives FDA Clearance for Clinical Study of SIM0237
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...
Fineline Cube
Ping An Life Insurance Reports Q3 Results, Advances Healthcare Strategy
Ping An Life Insurance Company of China Ltd released its 2022 Q3 financial report, showing...
United Labs Gains NMPA Approval for Ozempic Biosimilar IND
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that the National Medical Products...
China’s NMPA Issues New Drug Recall Management Measures
The National Medical Products Administration (NMPA) has released the “Drug Recall Management Measures,” which took...
AccuMedical’s Blood Flow-Guided Stent Wins NMPA Approval for Brain Aneurysms
AccuMedical Beijing Ltd has secured approval from China’s National Medical Products Administration (NMPA) for its...
InxMed and Huaota Bio Partner to Develop Novel Solid Tumor Combination Therapy
China-based InxMed (Nanjing) Co., Ltd has entered into a strategic partnership with Shanghai Huaota Biopharmaceutical...
LEPU ScienTech Medical Technology Sets IPO Price Range Ahead of Hong Kong Listing
China-based LEPU ScienTech Medical Technology (Shanghai) Co., Ltd is gearing up for an initial public...
WuXi AppTec Posts Stellar Q3 2022 Results with 209% Profit Surge
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its Q3 2022 financial...
OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma
Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...
Novartis Q3 Revenues Rise 4% YOY; China Sales Expand Despite COVID Lockdowns
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported a 4% year-on-year (YOY) increase in global...
ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs
China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a...
Ascentage Pharma Files for Phase Ib/II Study of Bcl-2 Inhibitor in Systemic Lupus Erythematosus
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the submission of a clinical filing with the...
Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving regulatory clearance in Australia to...
ArieMedi Secures Series A+ Financing to Expand Precision Navigation Solutions
ArieMedi Medical Science, a leading precision navigation solutions provider based in Beijing, has announced the...
ClinBrain Raises RMB 200 Million in Series C Financing to Boost Medical Big Data
Shanghai-based ClinBrain, a leading clinical data repository (CDR) and medical big data services provider, has...
Covis Pharma’s COPD Therapies Show Positive Results in Phase III AVANT Trial
Luxembourg-based Covis Pharma Group has released positive topline data from its Phase III AVANT trial,...
Huadong Medicine Reports 10.4% Revenue Growth in Q3 2022
Huadong Medicine Co., Ltd (SHE: 000963) has published its Q3 2022 financial report, revealing robust...
CSPC Receives CDE Approval for Generic Version of Pfizer’s Xeljanz
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has announced that it has received market...
Giant Biogene Set for IPO on Hong Kong Stock Exchange to Raise Funds for Expansion
China-based medical aesthetics company Giant Biogene Holding Co., Ltd (HKG: 2367) has announced plans to...
BIMI International Medical to Sell Off Underperforming Subsidiary Chongqing Zhuoda
China-based BIMI International Medical Inc. (OTCMKTS: BIMI), a wholesaler of drugs and healthcare products, has...